CHRISTEN DAVIS: Open Payments
NPI 1124344841 · BURKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$494 in 23 payments from 7 companies in 2025. Trend: 2023 $642 · 2024 $671 · 2025 $494
Food & beverage: $494
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 9 | $159 |
| GENZYME CORPORATION | 3 | $99 |
| Novartis Pharmaceuticals Corporation | 4 | $87 |
| AstraZeneca Pharmaceuticals LP | 4 | $86 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| Amgen Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
Products named: DUPIXENT, TRELEGY ELLIPTA, NUCALA, TEZSPIRE, Rhapsido, FASENRA, NEFFY, TAKHZYRO.
Industry payments across VA — which companies pay providers there.
